![]() The drug was originally researched as a treatment for cardiovascular diseases such as hypertension and angina, but focus quickly shifted to ED with the success of another PDE5 inhibitor, sildenafil (Viagra), which had been developed by Pfizer. ![]() Tadalafil was initially formulated by Glaxo Wellcome (now GlaxoSmithKline) under a new drug development partnership between Glaxo and Icos that began in August 1991. In addition to ED and PAH, tadalafil has undergone clinical trials for the treatment of benign prostatic hyperplasia and for female sexual dysfunction. It is a phosphodiesterase type 5 (PDE5) inhibitor, similar in function to sildenafil. Sold as Cialis and initially codenamed IC351, tadalafil is a drug prescribed for erectile dysfunction (ED) and approved for pulmonary arterial hypertension (PAH). A former Icos manager named short-sighted leadership by Clark as a factor in the failure of the company to develop any other successful drugs apart from Cialis. George Rathmann, seen as a guiding father to Icos, left the company in February 2000, and was replaced as CEO and chairman by Paul Clark, a former executive at Abbott Laboratories. Icos went public on June 6, 1991, raising $36 million. The company initially had temporary offices in downtown Seattle, but moved to Bothell in September 1990. The founders raised $33 million in July 1990 from many investors, including Bill Gates – who at the time was the largest shareholder, with 10% of the equity. The name Icos comes from icosahedron, a 20-sided polyhedron, which is the shape of many viruses, and was chosen because the founders originally thought retroviruses might be involved in inflammation. Icos was formed with the goal of developing new drugs to treat the underlying causes of inflammatory diseases and halt the disease process in the early stages. Icos was founded in 1989 by George Rathmann, Robert Nowinski, and Christopher Henney, each of whom had previously started another biotechnology company: Rathmann had created Amgen Nowinski had launched Genetic Systems, later sold to Bristol-Myers Squibb and Henney co-founded Immunex, later sold to Amgen. CMC Biologics, a Danish contract manufacturer, bought the remnants of Icos and retained the remaining employees. Eli Lilly acquired Icos in January 2007, and most of Icos's workers were laid off soon after. LeukArrest, a drug to treat shock, and Pafase, developed for sepsis, were both tested in phase III clinical trials, but testing was discontinued after unpromising results during the trials. Cialis was the only drug developed by the company to be approved. Boosted by a unique advertising campaign led by the Grey Worldwide Agency, sales from Cialis allowed Icos to become profitable in 2006. This drug was discovered by GlaxoSmithKline, developed by Icos, and manufactured and marketed in partnership with Eli Lilly. ![]() Icos is best known for the development of tadalafil (Cialis), a drug used to treat erectile dysfunction. Icos also manufactured antibodies for other biotechnology companies. During its 17-year history, the company conducted clinical trials of twelve drugs, three of which reached the last phase of clinical trials. Icos focused on the development of drugs to treat inflammatory disorders. It was founded in 1989 by David Blech, Isaac Blech, Robert Nowinski, and George Rathmann, a pioneer in the industry and chief executive officer (CEO) and co-founder of Amgen. state of Washington, before it was sold to Eli Lilly and Company in 2007. The P/E ratio is the most commonly used of these ratios because it focuses on the Isonics' earnings, one of the primary drivers of an investment's value.Icos Corporation (trademark ICOS) was an American biotechnology company and the largest biotechnology company in the U.S. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. This model doesn't attempt to find an intrinsic value for Isonics' Stock. ![]() Comparative valuation analysis is a catch-all model that can be used if you cannot value Isonics by discounting back its dividends or cash flows. The ratio of Shares Outstanding to Price to Sales for Isonics is about 279,980,000,000 . It is currently regarded as number one stock in price to sales category among related companies. ![]() Isonics is currently regarded as number one stock in shares outstanding category among related companies. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |